|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | challenges of advanced hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is an aggressive malignancy,resulting as the third cause of death by cancer each year. The management of patients with HCC is complex,as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging,clinical and biochemical parameters is routinely performed,a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer. Since the introduction of sorafenib in clinical practice,several phase Ⅲ clinical trials have failed to demonstrate any superiority over sorafenib in the frontline setting. Locoregional therapies have also been tested as first line treatment,but their role in advanced HCC is still matter of debate. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Therefore this review will focus on the range of experimental therapeutics for patients with advanced HCC and highlights the successes and failures of these treatments as well as areas for future development. Specifics such as dose limiting toxicity and safety profile in patients with liver dysfunction related to the underlying chronic liver disease should be considered when developing therapies in HCC. Finally,robust validated and reproducible surrogate end-points as well as predictive biomarkers should be defined in future randomized trials. | Stefano Colagrande Andrea L Inghilesi Sami Aburas Gian G Taliani Cosimo Nardi Fabio Marra | 2016 | World Journal of Gastroenterology2016，22，34： | 19 |
| 2 | Lonidamine:efficacy and safety in clinical trials for the treatment of solid tumors显示文摘 | Di Cosimo S Ferretti G Papaldo P | | 0，，3： | 1 |
| 3 | Technology and the issue of cost/benefit in diabetes 显示文摘 | Cosimo G Angelika M Francesco C | 2009 | Diabetes Metab Res Rev2009，25，1： | 1 |
| 4 | Catheter-Related Bloodstream Infection, Part Ⅰ: Pathogenesis Diagnosis, and Management显示文摘 | Ferretti G Mandala M Di Cosimo S | 2002 | Cancer Control2002，9，6： | 1 |
| 5 | Lonidamine , efficacy and safety in clinical trials for the treatment of solid tumors 显示文摘 | Di Cosimo S Ferretti G Papaldo P | 2003 | Drugs Today2003，39，3： | 1 |
| 6 | Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer 显示文摘 | Di Cosimo S Alimonti A Ferretti G | 2004 | Ann Oncol2004，15，7： | 1 |
| 7 | One-step MIBK synthesis: A new process from 2-propanol显示文摘 | Cosimo J I D Torres G Apesteguia C R | 2002 | J catalysis2002，208，1： | 1 |
| 8 | Catheter-re- lated bloodstream infections,part Ⅱ : specific pathogens and prevention显示文摘 | Ferretti G Mandala M Di Cosimo S | 2003 | Cancer Control2003，10，1： | 1 |
| 9 | Catheter-related bloodstream infections,part II:specific pathogens and prevention显示文摘 | Ferretti G Mandala M Di Cosimo S | 2003 | Cancer Control2003，0，1： | 1 |
| 10 | Catheter-re- lated bloodstream infections, part I: pathogenesis, diag- nosis, and management显示文摘 | Ferretti G Mandala M Di Cosimo S | 2002 | Cancer Control2002，9，6： | 1 |
| 11 | Catheter-related bloodstream infections, patti : patbogenesis, diag - nosis, and- management 显示文摘 | Ferretti G Mandala M Di Cosimo S | 2002 | Cancer Control2002，9，6： | 1 |
| 12 | Human epidermal growth factor receptor 2 (HER2) -positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications 显示文摘 | Montemurro F Di Cosimo S Arpino G | 2013 | Ann Oncol2013，24，1： | 1 |
| 13 | Incidence of chemotherapy-induced amenorrbea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer显示文摘 | Di Cosimo S Alimonti A Ferretti G | 2004 | Ann Oncol2004，15，7： | 1 |
| 14 | One - step MIBK synthe- sis:a new process from 2 - propanol 显示文摘 | Cosimo J I Torres G Apesteguia C R | 2002 | Journal of Catalysis2002，208，1： | 1 |
| 15 | 显示文摘 | Ferretti G Manadala M Cosimo SD | 2003 | Infect Oncol2003，10，1： | 1 |
| 16 | Docetaxel in advanced gastric cancer:review of the main clinical trials显示文摘 | Di Cosimo S Ferretti G Fazio N | 2003 | Acta Oncologica2003，42，7： | 1 |
| 17 | Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer显示文摘 | Cosimo SD Alimonti A Ferretti G | 2004 | Ann Oncol2004，15，7： | 1 |
| 18 | Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer显示文摘 | Di Cosimo S Alimonti A Ferretti G | 2004 | Ann Oncol2004，15，7： | 1 |
| 19 | Docetaxel in advanced gastric cancer--review of the main clinical trials显示文摘 | Di Cosimo S Ferretti G Fazio N | 2003 | Acta Oncol2003，42，7： | 1 |
| 20 | Human epidermal growthfactor receptor 2 ( HER -2)- positive and hormone receptor -positive breast cancer: new insights into molecular interactions andclinical implications 显示文摘 | Montemurro F Di Cosimo S Arpino G | 2013 | Ann Oncol2013，24，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员